AR082913A2 - Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma - Google Patents
Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la mismaInfo
- Publication number
- AR082913A2 AR082913A2 ARP110103258A ARP110103258A AR082913A2 AR 082913 A2 AR082913 A2 AR 082913A2 AR P110103258 A ARP110103258 A AR P110103258A AR P110103258 A ARP110103258 A AR P110103258A AR 082913 A2 AR082913 A2 AR 082913A2
- Authority
- AR
- Argentina
- Prior art keywords
- effector
- bronchodilator
- pharmaceutical composition
- prepare
- related pathologies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Una composición farmacéutica para tratar el asma y patologías relacionadas en un mamífero, que comprende cantidades terapéuticamente efectivas de un broncodilatador y un efector, en donde dicho efector es un polisacárido sulfatado que comprende de 1 a alrededor 10 residuos de azúcar. La composición puede comprender además un portador farmacéuticamente aceptable. Preferiblemente, el broncodilatador es un agonista andrenérgico b2 seleccionado del grupo integrado por salmeterol, formoterol, bambuterol, albuterol, terbutalina, pirbuterol, bitolterol, metaproterenol, isoetarina, e isoproterenol. En forma preferida, el efector es un polisacárido N-sulfatado, como por ejemplo la heparina que puede ser una heparina de peso molecular ultra bajo (ULMWH) o una heparina de bajo peso molecular (LMWH). Uso de un broncodilatador y un efector para preparar una composición farmacéutica de utilidad en un método para prevenir la tolerancia al broncodilatador en un mamífero que lo necesite, y que comprende la administración de cantidades terapéuticamente efectivas del broncodilatador y del efector, en donde dicho efector es un polisacárido sulfatado que comprende de 1 a alrededor de 10 residuos de azúcar. De esta manera se puede prevenir la tolerancia a los mencionados agonistas adrenérgicos b2, empleados como broncodilatadores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10650798P | 1998-10-30 | 1998-10-30 | |
US09/362,540 US6235725B1 (en) | 1998-10-30 | 1999-07-28 | Methods and compositions for the prevention of tolerance to medications |
Publications (1)
Publication Number | Publication Date |
---|---|
AR082913A2 true AR082913A2 (es) | 2013-01-16 |
Family
ID=26803748
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990105443A AR023911A1 (es) | 1998-10-30 | 1999-10-28 | Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma |
ARP110103258A AR082913A2 (es) | 1998-10-30 | 2011-09-07 | Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990105443A AR023911A1 (es) | 1998-10-30 | 1999-10-28 | Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma |
Country Status (25)
Country | Link |
---|---|
US (1) | US6235725B1 (es) |
EP (1) | EP1124563B1 (es) |
JP (1) | JP4585121B2 (es) |
CN (2) | CN1329496A (es) |
AR (2) | AR023911A1 (es) |
AT (1) | ATE277621T1 (es) |
AU (1) | AU760119B2 (es) |
BR (1) | BR9915818A (es) |
CA (1) | CA2348926C (es) |
CO (1) | CO5160320A1 (es) |
CY (1) | CY1107493T1 (es) |
CZ (1) | CZ297914B6 (es) |
DE (1) | DE69920734T2 (es) |
ES (1) | ES2228173T3 (es) |
HK (1) | HK1041596A1 (es) |
HU (1) | HUP0302492A3 (es) |
IL (2) | IL142865A0 (es) |
IS (1) | IS2321B (es) |
NO (1) | NO333194B1 (es) |
NZ (1) | NZ511399A (es) |
PL (1) | PL195592B1 (es) |
PT (1) | PT1124563E (es) |
SK (1) | SK285150B6 (es) |
TW (1) | TW565451B (es) |
WO (1) | WO2000025723A2 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
ES2227268T3 (es) * | 2000-10-12 | 2005-04-01 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Nuevos polvos para inhalacion con contenido en tiotropio. |
US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US20030070679A1 (en) * | 2001-06-01 | 2003-04-17 | Boehringer Ingelheim Pharma Kg | Capsules containing inhalable tiotropium |
US20030191151A1 (en) * | 2001-10-26 | 2003-10-09 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US20030203930A1 (en) * | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
JP2003221335A (ja) | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
US6702997B2 (en) | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
US20030140920A1 (en) * | 2001-10-26 | 2003-07-31 | Dey L.P. | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma |
EP1511466B2 (en) * | 2002-02-18 | 2015-02-25 | Ockham Biotech Limited | Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd |
PT1549337E (pt) * | 2002-02-18 | 2014-11-17 | Ockham Biotech Ltd | Combinação de adnase i e glicosaminoglicanos para utilização em depuração de adn extracelular |
ES2565028T3 (es) * | 2002-02-18 | 2016-03-30 | Ockham Biotech Limited | Terapia de combinación para trastornos respiratorios |
ES2425392T3 (es) | 2002-03-20 | 2013-10-15 | Mannkind Corporation | Cartucho para un aparato de inhalación |
CA2483271A1 (en) * | 2002-04-25 | 2003-11-06 | Momenta Pharmaceuticals, Inc. | Methods and products for mucosal delivery |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
US7763280B2 (en) * | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
EP1625851A4 (en) * | 2003-05-16 | 2007-12-26 | Bbk Bio Corp | PREPARATION FOR PREVENTING CONTACT OF PATHOGEN BROOMS WITH A LIVING ORGANISM |
TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
US20050043343A1 (en) * | 2003-07-28 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
PL1791542T3 (pl) | 2004-08-23 | 2015-11-30 | Mannkind Corp | Sole diketopiperazyny do dostarczania leków |
AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
EP2497484A3 (en) | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
DK2570147T3 (da) | 2008-06-13 | 2018-01-29 | Mannkind Corp | Tørpulverinhalator og system til lægemiddelindgivelse |
KR101628410B1 (ko) | 2008-06-20 | 2016-06-08 | 맨카인드 코포레이션 | 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법 |
TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US8734845B2 (en) | 2009-06-12 | 2014-05-27 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
US20130090371A1 (en) * | 2010-04-20 | 2013-04-11 | President And Fellows Of Harvard College | Methods and compositions for inhibition of beta2-adrenergic receptor degradation |
RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
MY180552A (en) | 2011-04-01 | 2020-12-02 | Mannkind Corp | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
WO2013063160A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
CA2878457C (en) | 2012-07-12 | 2021-01-19 | Mannkind Corporation | Dry powder drug delivery systems and methods |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
CN114848614A (zh) | 2013-07-18 | 2022-08-05 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
CN104069497A (zh) * | 2014-06-27 | 2014-10-01 | 东莞市凯法生物医药有限公司 | 一种降低药物耐受性的组合物、方法及其应用 |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US20190070244A1 (en) * | 2017-06-30 | 2019-03-07 | The New Zealand Institute For Plant And Food Research Limited | Boysenberry compositions and methods of preparation and use thereof |
WO2019031972A1 (en) | 2017-08-08 | 2019-02-14 | Shaw Odette M | BOYSEN, APPLE AND CASSIS WOOL COMPOSITION AND METHODS FOR PREPARING AND USING SAME |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1195497B (it) | 1983-03-08 | 1988-10-19 | Opocrin Spa | Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina |
US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US5032679A (en) | 1988-12-15 | 1991-07-16 | Glycomed, Inc. | Heparin fragments as inhibitors of smooth muscle cell proliferation |
US5380716A (en) | 1988-12-15 | 1995-01-10 | Glycomed, Inc. | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation |
US5192548A (en) | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
US5714376A (en) | 1991-10-23 | 1998-02-03 | Massachusetts Institute Of Technology | Heparinase gene from flavobacterium heparinum |
AU663906B2 (en) | 1991-12-12 | 1995-10-26 | Glaxo Group Limited | Medicaments |
US5736124A (en) | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
JP3342484B2 (ja) * | 1991-12-18 | 2002-11-11 | アストラ・アクチエボラーグ | 新規な配合 |
US5690910A (en) * | 1995-08-18 | 1997-11-25 | Baker Norton Pharmaceuticals, Inc. | Method for treating asthma |
-
1999
- 1999-07-28 US US09/362,540 patent/US6235725B1/en not_active Expired - Lifetime
- 1999-10-13 DE DE69920734T patent/DE69920734T2/de not_active Expired - Lifetime
- 1999-10-13 CZ CZ20011518A patent/CZ297914B6/cs not_active IP Right Cessation
- 1999-10-13 NZ NZ511399A patent/NZ511399A/en not_active IP Right Cessation
- 1999-10-13 CN CN99813923A patent/CN1329496A/zh active Pending
- 1999-10-13 PT PT99971300T patent/PT1124563E/pt unknown
- 1999-10-13 HU HU0302492A patent/HUP0302492A3/hu not_active Application Discontinuation
- 1999-10-13 AU AU12051/00A patent/AU760119B2/en not_active Ceased
- 1999-10-13 PL PL99364727A patent/PL195592B1/pl unknown
- 1999-10-13 BR BR9915818-3A patent/BR9915818A/pt not_active Application Discontinuation
- 1999-10-13 CN CNB2004100629128A patent/CN100352448C/zh not_active Expired - Fee Related
- 1999-10-13 AT AT99971300T patent/ATE277621T1/de active
- 1999-10-13 JP JP2000579168A patent/JP4585121B2/ja not_active Expired - Fee Related
- 1999-10-13 SK SK590-2001A patent/SK285150B6/sk not_active IP Right Cessation
- 1999-10-13 EP EP99971300A patent/EP1124563B1/en not_active Expired - Lifetime
- 1999-10-13 IL IL14286599A patent/IL142865A0/xx active IP Right Grant
- 1999-10-13 WO PCT/US1999/024034 patent/WO2000025723A2/en active IP Right Grant
- 1999-10-13 ES ES99971300T patent/ES2228173T3/es not_active Expired - Lifetime
- 1999-10-13 CA CA2348926A patent/CA2348926C/en not_active Expired - Fee Related
- 1999-10-28 AR ARP990105443A patent/AR023911A1/es not_active Application Discontinuation
- 1999-10-29 CO CO99068642A patent/CO5160320A1/es unknown
- 1999-11-09 TW TW088118719A patent/TW565451B/zh not_active IP Right Cessation
-
2001
- 2001-04-27 NO NO20012097A patent/NO333194B1/no not_active IP Right Cessation
- 2001-04-27 IS IS5928A patent/IS2321B/is unknown
- 2001-04-30 IL IL142865A patent/IL142865A/en not_active IP Right Cessation
-
2002
- 2002-05-02 HK HK02103273.0A patent/HK1041596A1/zh unknown
-
2004
- 2004-12-06 CY CY20041101437T patent/CY1107493T1/el unknown
-
2011
- 2011-09-07 AR ARP110103258A patent/AR082913A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR082913A2 (es) | Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma | |
BR0309487A (pt) | Misturas de alcoxilato, processo para a preparação e uso das mesmas, e, agente de lavagem, limpeza, umedecimento, revestimento, adesão, desengraxamento de couro, retenção de umidade ou de tratamento de têxtil ou formulações cosméticas, farmacêuticas ou para a proteção de plantas | |
AR052221A1 (es) | Metodo para el tratamiento de la enfermedad poliquistosis renal | |
MX172913B (es) | Proceso para la preparacion de espumas rigidas de poliuretano que tienen una baja conductividad termica | |
GB2385524A (en) | Compositions and methods of use for extracts of magnoliaceae | |
BR9808641B1 (pt) | processo para preparação de uma forma de dosagem sólida, oral de rápida desintegração de uma substáncia farmaceuticamente ativa que possui um sabor inaceitável. | |
ES512464A0 (es) | Un procedimiento para la preparacion de un nuevo antitrombosico a base de oligosacaridos y polisacaridos. | |
ES2059321T3 (es) | Heparinas, fracciones y fragmentos de heparinas libres de edta, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
MX9300584A (es) | Mezcla de oligosacaridos sulfatados, procedimiento para su preparacion y composicion farmaceutica que la contiene. | |
SE8703971D0 (sv) | Losliga och/eller sonderdelbara tabletter och sett att framstella dessa | |
Adeyemi et al. | Gastrointestinal activity of the aqueous extract of a Nigerian polyherbal preparation | |
Stenstrom et al. | Inhibition by ethanol of forskolin-stimulated adenylate cyclase in a murine neuroblastoma clone (N1E-115) | |
US4921628A (en) | Cleaning composition for removal of PCBs | |
ICOCHEA | Influence of simplified surface treatments protocols on the bond strength between resin cements and reinforced glass-based ceramics | |
CO5580790A2 (es) | Composicion farmaceutica de fondaparinux sodio para el tratamiento de acs | |
Wang et al. | Experimental study of elbow joint stability following ulna coronoid process fractures | |
JPS5613486A (en) | Composite of scale removing agent | |
LEE et al. | Triscaphe Fusion in the Treatment of Kienbock's Disease: Comparison of Lunate Preservation and Excision | |
YOO et al. | Muscle Transposition for Repair of Skin Defects Over Exposed Bone | |
SUH et al. | 5 Cases of Extrapyramidal Symptoms after Haloperidol Premedication | |
Batbayar et al. | Polysaccharides from Mongolian plants and their effect on the complement system: I. Polysaccharides from plants of the Asteraceae family | |
Rah et al. | Clinical Study of Ipsilateral Fracture of the Femur and Tibia | |
Abdel Rahman A et al. | Management of recent tongue type calcaneal fractures by axial fixation | |
SHIN et al. | Treatment of Radial Head Fracture | |
Han et al. | The Experimental Study of Stone Fracture by Shock Wave (I) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |